Infigratinib is an inhibitor of fibroblast growth factor receptor 2 (FGFR2) and has shown promising therapeutic effects in previously treated FGFR2-mutant cholangiocarcinoma patients [38]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.